Frank Knuettel II, CEO of Chromocell Therapeutics Corp., was recently a guest on Benzinga's All-Access.

Chromocell is a clinical-stage biotech company focusing on novel pain treatments. The company's therapeutics target a specific channel in the body, NaV1.7, known for its role in pain. By blocking it, the company aims to stop pain signals from reaching the brain and spinal cord.

Chromocell is currently specifically targeting erythromelalgia, which causes intense burning pain, redness and increased skin temperature in the feet and sometimes the hands.